The phase 3 trial results for patients diagnosed with first-line unresectable liver cancer showed a 31% survival rate after three years
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.